At the news
? NEUTRALIMPACT 2/10 8-K filed Sep 8, 2026 at 07:05 ET
Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective September 8, 2026. This is a routine executive appointment with standard compensation terms, including a $550,000 base salary, an option for 450,000 shares, and a performance-based RSU award. No red flags such as unexpected departures or resignations are present, making this a neutral event.
- Jennifer Fulk appointed CFO, principal financial officer, and principal accounting officer effective September 8, 2026.
- Annual base salary of $550,000, with eligibility for an annual discretionary bonus of up to 45% of base salary.
- Received an option to purchase 450,000 shares vesting over 4 years and a performance-based RSU award covering 173,438 shares.
- No unexpected departures or resignations; the appointment is a standard executive change.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access